The headquarters of Eli Lilly in Indianapolis, Ind., on March 17, 2024. Scott Olson/Getty ImagesEli Lilly and Company announced on April 20 that it will acquire clinical-stage cancer biotechnology company Kelonia Therapeutics for $7 billion.The acquisition expands Eli Lilly’s pipeline into experimental cancer treatments, specifically in vivo genetic therapy. Kelonia Therapeutics is advancing CAR-T genetic medicines that reprogram a cancer patient’s T-cells to fight cancer and underlying diseases. Its lead program, KLN-1010, targets cancerous myeloma plasma cells that affect bone marrow.
23.9
C
Ottawa
Wednesday, June 17, 2026
The Alliance Press is the world leader in online chained news and information and seeks to inform, engage and empower the world. We expose the information that wasn't known before or current events broadcast over the radio, television, online or in print media. Our content is now available through your mobile phone. No matter where your on-the-go lifestyle takes you, TAP brings the news directly to you.
More from CN
Contact
© The Alliance Media Group design by CODEUS